Details for Patent: 9,468,639
✉ Email this page to a colleague
Title: | Treating sexual desire disorders with flibanserin |
Abstract: | The invention relates to the use of flibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire. |
Inventor(s): | Borsini; Franco (Bad Waldsee, DE), Evans; Kenneth Robert (Toronto, CA) |
Assignee: | Sprout Pharmaceuticals, Inc. (Raleigh, NC) |
Filing Date: | Mar 06, 2015 |
Application Number: | 14/640,055 |
Claims: | 1. A method of treating decreased sexual desire in a patient, comprising administering a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to the patient to treat decreased sexual desire. 2. The method according to claim 1, wherein the patient is female. 3. The method according to claim 1, wherein the patient is male. 4. The method according to claim 1, wherein the amount administered is between about 0.1 mg and 400 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 5. The method according to claim 1, wherein the amount administered is between about 1 mg and 300 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 6. The method according to claim 1, wherein the amount administered is in a dosage unit containing between about 0.01 mg and 100 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 7. The method according to claim 1, wherein the amount administered is in a dosage unit containing between about 0.1 mg and 50 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 8. A method of treating absent sexual desire in a patient, comprising administering a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to the patient to treat decreased sexual desire. 9. The method according to claim 8, wherein the patient is female. 10. The method according to claim 8, wherein the patient is male. 11. The method according to claim 8, wherein the amount administered is between about 2 mg and 200 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 12. The method according to claim 8, wherein the amount administered is between about 0.1 mg and 100 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 13. The method according to claim 8, wherein the amount administered is in a dosage unit containing about 150 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 14. A method of treating inhibited sexual desire in a patient, comprising administering a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to the patient to treat decreased sexual desire. 15. The method according to claim 14, wherein the patient is female. 16. The method according to claim 14, wherein the patient is male. 17. The method according to claim 14, wherein the amount administered is between about 0.1 mg and 400 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 18. The method according to claim 14, wherein the amount administered is in a dosage unit containing about 100 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 19. The method according to claim 14, wherein the amount administered is in a dosage unit containing about 80 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof. 20. The method according to claim 14, wherein the amount administered is in a dosage unit containing about 50 mg of flibanserin or a pharmaceutically acceptable acid addition salt thereof. |